表紙
市場調查報告書

遺傳性血管水腫市場:全球產業分析,規模,佔有率,成長,趨勢,預測(2019∼2027年)

Hereditary Angioedema Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

出版商 Transparency Market Research 商品編碼 920535
出版日期 內容資訊 英文 184 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
遺傳性血管水腫市場:全球產業分析,規模,佔有率,成長,趨勢,預測(2019∼2027年) Hereditary Angioedema Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
出版日期: 2019年11月29日內容資訊: 英文 184 Pages
簡介

本報告提供遺傳性血管水腫市場相關調查,彙整市場趨勢與預測,市場規模,主要加入企業,各地區趨勢相關資訊。

第1章 序論

第2章 假設和調查方法

第3章 摘要整理

第4章 市場概要

  • 簡介
  • 概要
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會
  • 市場分析與預測

第5章 市場預測

  • 開發平台分析
  • 孤兒藥壟斷性方案
  • 主要的合併·收購
  • 疾病概要
  • 各主要國家罹患率

第6章 市場分析與預測:各類藥物

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場價值預測
    • C1酯酶抑製劑
    • 選擇性緩激肽B2受體拮抗劑
    • 激肽釋放酶抑製劑
    • 其他
  • 市場魅力度

第7章 市場分析與預測:各給藥途徑

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場價值預測
    • 血管內
    • 皮下注射
    • 口服
  • 市場魅力度

第8章 市場分析與預測:各流通管道

  • 簡介和定義
  • 主要調查結果/趨勢
  • 市場價值預測
    • 院內藥局
    • 零售藥局
    • 其他
  • 市場魅力度

第9章 市場分析與預測:各地區

  • 主要調查結果
  • 市場價值預測
    • 北美
    • 歐洲
    • 其他地區
  • 市場魅力度

第10章 北美

第11章 歐洲

第12章 其他地區

第13章 競爭環境

  • 競爭矩陣
  • 市場佔有率分析
  • 企業簡介
目錄

Hereditary Angioedema Treatment Market - Scope of the Report

TMR's report on the global hereditary angioedema treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the market for the forecast period of 2019 to 2027. The report provides the overall market revenue of the global hereditary angioedema treatment market for the period of 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global hereditary angioedema treatment market for the forecast period.

The report has been prepared after extensive primary and secondary research. Primary research involved bulk of the research efforts, wherein, analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global hereditary angioedema treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of the top-down and bottom-up approach to study various phenomena in the global hereditary angioedema treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global hereditary angioedema treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global hereditary angioedema treatment market.

The report delves into the competitive landscape of the global hereditary angioedema treatment market. Key players operating in the global hereditary angioedema treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the global hereditary angioedema treatment market that have been profiled in this report.

Key Questions Answered in the Hereditary Angioedema Treatment market Report

What is the sales/revenue expected to be generated by each drug class and route of administration segment of the hereditary angioedema treatment market across all regions during the forecast period?

What are the opportunities in the global hereditary angioedema treatment market?

What are the major drivers, restraints, opportunities, and threats in the market?

Which regional market is likely to expand at the fastest CAGR during the forecast period?

Which hereditary angioedema drug class, route of administration, and distribution channel segments are expected to generate the highest revenue, globally, in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?

What was the market share or position of different companies operating in the global market in 2018?

Global Hereditary Angioedema Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global hereditary angioedema treatment market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, pipeline analysis, orphan drug exclusivity scenario, key mergers & acquisitions, and disease overview.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small sections. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hereditary Angioedema Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Class Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2017-2027
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

  • 5.1. Pipeline Analysis
  • 5.2. Orphan Drug Exclusivity Scenario
  • 5.3. Key Merger & Acquisitions
  • 5.4. Disease Overview
  • 5.5. Disease Prevalence-Global and Key Countries

6. Global Hereditary Angioedema Treatment Market Analysis and Forecast, by Drug Class, 2017-2027

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2027
    • 6.3.1. C1 Esterase Inhibitor
      • 6.3.1.1. Plasma Products
        • 6.3.1.1.1. Berinert
        • 6.3.1.1.2. Cinryze
        • 6.3.1.1.3. Haegarda
      • 6.3.1.2. Recombinant Products
        • 6.3.1.2.1. Ruconest
    • 6.3.2. Selective Bradykinin B2 Receptor Antagonist
      • 6.3.2.1. Firazyr
    • 6.3.3. Kallikrein Inhibitor
      • 6.3.3.1. Kalbitor
      • 6.3.3.2. Takhzyro
    • 6.3.4. Others
      • 6.3.4.1. Conventional Drugs
      • 6.3.4.2. Pipeline Drugs
  • 6.4. Market Attractiveness By Drug Class

7. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Route of Administration, 2017-2027

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2027
    • 7.3.1. Intravenous
    • 7.3.2. Subcutaneous Injection
    • 7.3.3. Oral
  • 7.4. Market Attractiveness, by Route of Administration

8. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Distribution Channel, 2017-2027

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2027
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Others
  • 8.4. Market Attractiveness, by Distribution Channel

9. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Region, 2017-2027

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Rest of the World
  • 9.3. Market Attractiveness, by Country/Region

10. North America Hereditary Angioedema Treatment Market Analysis and Forecast, 2017-2027

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2027
    • 10.2.1. C1 Esterase Inhibitor
      • 10.2.1.1. Plasma Products
        • 10.2.1.1.1. Berinert
        • 10.2.1.1.2. Cinryze
        • 10.2.1.1.3. Haegarda
      • 10.2.1.2. Recombinant Products
        • 10.2.1.2.1. Ruconest
    • 10.2.2. Selective Bradykinin B2 Receptor Antagonist
      • 10.2.2.1. Firazyr
    • 10.2.3. Kallikrein Inhibitor
      • 10.2.3.1. Kalbitor
      • 10.2.3.2. Takhzyro
    • 10.2.4. Others
      • 10.2.4.1. Conventional Drugs
      • 10.2.4.2. Pipeline Drugs
  • 10.3. Market Value Forecast, by Route of Administration, 2017-2027
    • 10.3.1. Intravenous
    • 10.3.2. Subcutaneous Injection
    • 10.3.3. Oral
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2027
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2027
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Route of Administration
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Hereditary Angioedema Treatment Market Analysis and Forecast, 2017-2027

  • 11.1. .Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2027
    • 11.2.1. C1 Esterase Inhibitor
      • 11.2.1.1. Plasma Products
        • 11.2.1.1.1. Berinert
        • 11.2.1.1.2. Cinryze
        • 11.2.1.1.3. Haegarda
      • 11.2.1.2. Recombinant Products
        • 11.2.1.2.1. Ruconest
    • 11.2.2. Selective Bradykinin B2 Receptor Antagonist
      • 11.2.2.1. Firazyr
    • 11.2.3. Kallikrein Inhibitor
      • 11.2.3.1. Kalbitor
      • 11.2.3.2. Takhzyro
    • 11.2.4. Others
      • 11.2.4.1. Conventional Drugs
      • 11.2.4.2. Pipeline Drugs
  • 11.3. Market Value Forecast, by Route of Administration, 2017-2027
    • 11.3.1. Intravenous
    • 11.3.2. Subcutaneous Injection
    • 11.3.3. Oral
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2027
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2027
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Route of Administration
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Rest of the World Hereditary Angioedema Treatment Market Analysis and Forecast, 2017-2027

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2027
    • 12.2.1. C1 Esterase Inhibitor
      • 12.2.1.1. Plasma Products
        • 12.2.1.1.1. Berinert
        • 12.2.1.1.2. Cinryze
        • 12.2.1.1.3. Haegarda
      • 12.2.1.2. Recombinant Products
        • 12.2.1.2.1. Ruconest
    • 12.2.2. Selective Bradykinin B2 Receptor Antagonist
      • 12.2.2.1. Firazyr
    • 12.2.3. Kallikrein Inhibitor
      • 12.2.3.1. Kalbitor
      • 12.2.3.2. Takhzyro
    • 12.2.4. Others
      • 12.2.4.1. Conventional Drugs
      • 12.2.4.2. Pipeline Drugs
  • 12.3. Market Value Forecast, by Route of Administration, 2017-2027
    • 12.3.1. Intravenous
    • 12.3.2. Subcutaneous Injection
    • 12.3.3. Oral
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2027
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Others
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Drug Class
    • 12.5.2. By Route of Administration
    • 12.5.3. By Distribution Channel

13. Competitive Landscape

  • 13.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 13.2. Market Share Analysis, by Company, 2018
  • 13.3. Company Profiles
    • 13.3.1. Shire plc (Takeda Pharmaceutical Company Limited)
      • 13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.1.2. Company Financials
      • 13.3.1.3. Growth Strategies
      • 13.3.1.4. SWOT Analysis
    • 13.3.2. CSL Limited
      • 13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.2.2. Company Financials
      • 13.3.2.3. Growth Strategies
      • 13.3.2.4. SWOT Analysis
    • 13.3.3. Pharming Group N.V.
      • 13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.3.2. Company Financials
      • 13.3.3.3. Growth Strategies
      • 13.3.3.4. SWOT Analysis
    • 13.3.4. Ionis Pharmaceuticals, Inc.
      • 13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.4.2. Company Financials
      • 13.3.4.3. Growth Strategies
      • 13.3.4.4. SWOT Analysis
    • 13.3.5. BioCryst Pharmaceuticals, Inc.
      • 13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.5.2. Company Financials
      • 13.3.5.3. Growth Strategies
      • 13.3.5.4. SWOT Analysis
    • 13.3.6. KalVista Pharmaceuticals Ltd.
      • 13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.6.2. Company Financials
      • 13.3.6.3. Growth Strategies
      • 13.3.6.4. SWOT Analysis
    • 13.3.7. Attune Pharmaceuticals
      • 13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 13.3.7.2. Company Financials
      • 13.3.7.3. Growth Strategies
      • 13.3.7.4. SWOT Analysis

List of Tables

  • Table 01: Pipeline Analysis, by Phase III
  • Table 02: Pipeline Analysis, by Phase II and Phase I
  • Table 03: Pipeline Analysis, by Preclinical Trial
  • Table 04: Orphan Drug Exclusivity
  • Table 05: Key Mergers & Acquisition in the Hereditary Angioedema Treatment Market
  • Table 06: Disease Overview by Type of HAE
  • Table 07: Reported and Estimated Cases of HAE, by Country
  • Table 08: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 09: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017-2027
  • Table 10: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017-2027
  • Table 11: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017-2027
  • Table 12: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017-2027
  • Table 13: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 14: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 15: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2027
  • Table 16: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2027
  • Table 17: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 18: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017-2027
  • Table 19: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017-2027
  • Table 20: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017-2027
  • Table 21: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017-2027
  • Table 22: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 23: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 24: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 25: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 26: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017-2027
  • Table 27: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017-2027
  • Table 28: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017-2027
  • Table 29: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017-2027
  • Table 30: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 31: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 32: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 33: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017-2027
  • Table 34: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017-2027
  • Table 35: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017-2027
  • Table 36: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017-2027
  • Table 37: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2027
  • Table 38: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027

List of Figures

  • Figure 01: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
  • Figure 02: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2017-2027
  • Figure 03: Global Hereditary Angioedema Treatment Market Value Share, by Drug Class, 2018
  • Figure 04: Global Hereditary Angioedema Treatment Market Value Share, by Route of Administration, 2018
  • Figure 05: Global Hereditary Angioedema Treatment Market Value Share, by Distribution Channel, 2018
  • Figure 06: Global Hereditary Angioedema Treatment Market Value Share, by Route of Administration, 2018
  • Figure 07: Global Hereditary Angioedema Treatment Market - Key Drivers and Restraints
  • Figure 08: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 09: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by C1 Esterase Inhibitor, 2017-2027
  • Figure 10: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Selective Bradykinin B2 Receptor Antagonist, 2017-2027
  • Figure 11: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Kallikrein Inhibitor, 2017-2027
  • Figure 12: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
  • Figure 13: Global Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019-2027
  • Figure 14: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
  • Figure 15: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Intravenous, 2017-2027
  • Figure 16: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous Injection, 2017-2027
  • Figure 17: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017-2027
  • Figure 18: Global Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019-2027
  • Figure 19: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 20: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2027
  • Figure 21: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2027
  • Figure 22: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
  • Figure 23: Global Hereditary Angioedema Treatment Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 24: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Region, 2018 and 2027
  • Figure 25: Global Hereditary Angioedema Treatment Market Attractiveness Analysis, by Region, 2019-2027
  • Figure 26: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2019-2027
  • Figure 27: North America Hereditary Angioedema Treatment Market Value Share, by Country, 2018 and 2027
  • Figure 28: North America Hereditary Angioedema Treatment Market Attractiveness, by Country, 2019-2027
  • Figure 29: North America Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 30: North America Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019-2027
  • Figure 31: North America Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
  • Figure 32: North America Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019-2027
  • Figure 33: North America Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 34: North America Hereditary Angioedema Treatment Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 35: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2019-2027
  • Figure 36: Europe Hereditary Angioedema Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • Figure 37: Europe Hereditary Angioedema Treatment Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 38: Europe Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 39: Europe Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019-2027
  • Figure 40: Europe Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
  • Figure 41: Europe Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019-2027
  • Figure 42: Europe Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 43: Europe Hereditary Angioedema Treatment Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 44: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2019-2027
  • Figure 45: Rest of the World Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 46: Rest of the World Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019-2027
  • Figure 47: Rest of the World Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
  • Figure 48: Rest of the World Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019-2027
  • Figure 49: Rest of the World Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 50: Rest of the World Hereditary Angioedema Treatment Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 51: Global Hereditary Angioedema Treatment Market Share Analysis, by Company (2018)
  • Figure 52: Shire plc, Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2017
  • Figure 53: Shire plc, Breakdown of Net Sales (%), by Geography, 2017
  • Figure 54: Shire plc, Breakdown of Net Sales (%), by Therapeutic areas, 2017
  • Figure 55: Shire plc, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 56: CSL Behring, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 57: CSL Behring, Breakdown of Net Sales (%), by Geography, 2018
  • Figure 58: CSL Behring, Breakdown of Net Sales (%), by Product Division/Therapy, 2018
  • Figure 59: CSL Limited, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 60: Pharming Group NV, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 61: Pharming Group NV, Breakdown of Net Sales (%), by Geography, 2018
  • Figure 62: Pharming Group NV, Region-wise Breakdown of Net Sales (%), by Ruconest, 2018
  • Figure 63: Pharming Group NV, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 64: Ionis Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 65: Ionis Pharmaceuticals, Inc., Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 66: Ionis Pharmaceuticals, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 67: BioCryst Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 68: BioCryst Pharmaceuticals, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 69: KalVista Pharmaceuticals Ltd., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 70: KalVista Pharmaceuticals Ltd., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018
Back to Top